Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection.
Bini EJ, Bräu N, Currie S, Shen H, Anand BS, Hu KQ, Jeffers L, Ho SB, Johnson D, Schmidt WN, King P, Cheung R, Morgan TR, Awad J, Pedrosa M, Chang KM, Aytaman A, Simon F, Hagedorn C, Moseley R, Ahmad J, Mendenhall C, Waters B, Strader D, Sasaki AW, Rossi S, Wright TL. Bini EJ, et al. Among authors: wright tl. Am J Gastroenterol. 2005 Aug;100(8):1772-9. doi: 10.1111/j.1572-0241.2005.41860.x. Am J Gastroenterol. 2005. PMID: 16086714
Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.
Department of Veterans Affairs Hepatitis C Resource Center; Yee HS, Currie SL, Darling JM, Wright TL. Department of Veterans Affairs Hepatitis C Resource Center, et al. Among authors: wright tl. Am J Gastroenterol. 2006 Oct;101(10):2360-78. doi: 10.1111/j.1572-0241.2006.00754.x. Am J Gastroenterol. 2006. PMID: 17032203
Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.
Bräu N, Bini EJ, Currie S, Shen H, Schmidt WN, King PD, Ho SB, Cheung RC, Hu KQ, Anand BS, Simon FR, Aytaman A, Johnson DP, Awad JA, Ahmad J, Mendenhall CL, Pedrosa MC, Moseley RH, Hagedorn CH, Waters B, Chang KM, Morgan TR, Rossi SJ, Jeffers LJ, Wright TL; VA-HCV-001 Study Group. Bräu N, et al. Among authors: wright tl. J Viral Hepat. 2006 Apr;13(4):242-9. doi: 10.1111/j.1365-2893.2005.00682.x. J Viral Hepat. 2006. PMID: 16611190
239 results